Medigene and Difa Cooper enter into agreement for the commercialization of Veregen® in Italy
(Thomson Reuters ONE) -
Medigene AG /
Medigene and Difa Cooper enter into agreement for the commercialization of
Veregen® in Italy
. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 06 August, 2013. Medigene AG (MDG, Frankfurt, Prime
Standard) announces the conclusion of an exclusive license and supply agreement
with Difa Cooper SPA, the Italian subsidiary of the Spanish pharmaceutical
company IFC (Industrial Farmaceutica Cantabria), for the supply and
commercialization of Veregen(®) in Italy. After approval Difa Cooper will
promote and distribute the drug for the treatment of genital warts. In addition
to a one-time upfront payment, Medigene will also obtain revenues from milestone
payments, from the supply of the finished product, as well as double-digit
royalties on the future sales of Veregen(®).
Dr. Frank Mathias, Chief Executive Officer of Medigene AG, comments: "We are
glad that we will now be able to open up the Italian market with this marketing
partnership. Difa Cooper is a renowned Italian pharmaceutical company with a
focus on dermatology, and will approach all relevant target groups with the
drug. We have established sales networks for Veregen(®) in almost all European
countries, and the drug is currently available on prescription in six European
countries."
Dr. Stefano Fatelli, General Manager of Difa Cooper, of Difa Cooper, adds: "This
innovative ointment for the topical treatment of genital warts complements our
product portfolio and strengthens our competitive position. We look forward to
driving forward the approval and commercialization of Veregen(®) in Italy."
Veregen(®) is already being marketed in the USA (by Fougera), in Germany,
Austria and Switzerland (by Abbott), in Spain (by Bial), in Serbia (by
Pharmanova) as well as in the Netherlands (by Will-Pharma) and approved in
further countries. Market approvals and the launch of Veregen(® )in several
other countries are pending in 2013. The marketing authorization application for
Italy and the remaining European countries is in preparation. Medigene has
entered into several marketing partnerships for Veregen® across Europe, Asia,
and America, and is planning to continue this global licensing strategy to
further leverage the product's market potential.
About Veregen(®): Veregen(®), a topical treatment for external genital or
perianal warts, contains a concentrate of catechins with a complex defined
composition extracted from green tea leaves. In its current treatment guidelines
for sexually transmitted diseases, the US Center for Disease Control and
Prevention recommends Sinecatechins 15% ointment (Veregen(®)) as a possible
option for treating genital warts. In addition, Sinecatechins 10% & 15% ointment
(Veregen(®)) has been included in the current European guideline on the
treatment of genital warts, the 2012 European Guideline for the Management of
Anogenital Warts.
Difa Cooper: Difa Cooper is a pharmaceutical company specializing in dermatology
and has been operating in the Italian pharmacies market for more than 50 years.
It is part of the IFC Group (Industrial Farmaceutica Cantabria) based in Madrid.
IFC develops, manufactures, and distributes dermatological products,
pharmaceuticals, cosmetics, nutritional supplements, and technologies. The IFC
sales network covers more than 50 countries worldwide. For more information,
please visit http://www.difacooper.com.
Medigene AG (Frankfurt: MDG, Prime Standard) is a publicly listed biotech
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene is the first German biotech company to generate revenues from
a marketed product (Veregen(®)), which is distributed by partner companies.
Medigene also has two drug candidates undergoing clinical trials, EndoTAG(®)-1
und RhuDex(®), and is developing an innovative vaccine technology. For further
details, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) and Veregen(®) are registered trademarks of Medigene AG. Polyphenon
E(® )is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or
licensed in select locations only.
Contact
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as PDF:
http://hugin.info/132073/R/1721187/573184.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via Thomson Reuters ONE
[HUG#1721187]
Unternehmensinformation / Kurzprofil:
Datum: 06.08.2013 - 07:30 Uhr
Sprache: Deutsch
News-ID 284819
Anzahl Zeichen: 6155
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 221 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene and Difa Cooper enter into agreement for the commercialization of Veregen® in Italy"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
